Anidulafungin A Potent Antifungal that Targets Candida and Aspergillus

被引:11
作者
Ghannoum, Mahmoud [1 ,2 ]
D'Angelo, Maurissa
机构
[1] Univ Hosp Cleveland, Dept Dermatol, Ctr Med Mycol, Wearn Bldg,Room 320,LKSD 5028,2109 Adelbert Rd, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Cleveland, OH 44106 USA
关键词
D O I
10.1097/01.idc.0000170684.37817.6c
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Anidulafungin (LY-303366, VER002) is a semisynthetic derivative of echinocandin B and a potent antifungal agent active against a wide spectrum of fungal pathogens. We reviewed published papers, abstracts, and data to provide an overview focusing on the microbiology of anidulafungin and its promise for treating fungal infections. Anidulafungin was found to have excellent in vivo and in vitro activity against various Candida, Aspergillus, and other pathogenic fungi, often at lower concentrations than other currently used drugs. Additionally, anidulafungin inhibits Candida albicans biofilm growth in vitro. Anidulafungin was also found to have low or no toxicity in the animal models reviewed. This is likely because anidulafungin and other candins inhibit the synthesis of 1,3-beta-D-glucan, a fungus-specific component of the cell wall. Anidulafungin promises to be an effective and safe agent for the treatment of candidiasis and invasive aspergillosis.
引用
收藏
页码:165 / 178
页数:14
相关论文
共 54 条
[1]   Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae [J].
Agarwal, AK ;
Rogers, PD ;
Baerson, SR ;
Jacob, MR ;
Barker, KS ;
Cleary, JD ;
Walker, LA ;
Nagle, DG ;
Clark, AM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (37) :34998-35015
[2]   Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens:: a comparative study with M27-A microdilution method [J].
Arévalo, MP ;
Carrillo-Muñoz, AJ ;
Salgado, J ;
Cardenes, D ;
Brió, S ;
Quindós, G ;
Espinel-Ingroff, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) :163-166
[3]   Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo [J].
Bartlett, MS ;
Current, WL ;
Goheen, MP ;
Boylan, CJ ;
Lee, CH ;
Shaw, MM ;
Queener, SF ;
Smith, JW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1811-1816
[4]  
Bartlett MS, 1998, 98 M SAN FRANC APR 2
[5]   Biofilm formation by the fungal pathogen Candida albicans:: Development, architecture, and drug resistance [J].
Chandra, J ;
Kuhn, DM ;
Mukherjee, PK ;
Hoyer, LL ;
McCormick, T ;
Ghannoum, MA .
JOURNAL OF BACTERIOLOGY, 2001, 183 (18) :5385-5394
[6]   In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients [J].
Chávez, M ;
Bernal, S ;
Valverde, A ;
Gutierrez, MJ ;
Quindós, G ;
Mazuelos, EM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (05) :697-700
[7]   Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B [J].
Cuenca-Estrella, M ;
Mellado, E ;
Díaz-Guerra, TM ;
Monzón, A ;
Rodríguez-Tudela, JL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (03) :475-477
[8]   Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors [J].
Douglas, CM ;
DIppolito, JA ;
Shei, GJ ;
Meinz, M ;
Onishi, J ;
Marrinan, JA ;
Li, W ;
Abruzzo, GK ;
Flattery, A ;
Bartizal, K ;
Mitchell, A ;
Kurtz, MB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2471-2479
[9]   Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans [J].
Ernst, EJ ;
Klepser, ME ;
Pfaller, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1108-1111
[10]   Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2950-2956